Valuation : Fortress Biotech, Inc.

Market Cap 90.38M 77.71M 73.11M 66.72M 125M 8.57B 125M 866M 335M 4.38B 339M 332M 13.94B P/E 2026 *
1.06x
P/E 2027 * -2.71x
Enterprise Value 90.38M 77.71M 73.11M 66.72M 125M 8.57B 125M 866M 335M 4.38B 339M 332M 13.94B EV / Sales 2026 *
1.15x
EV / Sales 2027 * 0.8x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week+1.12%
Current month-0.91%
1 month+1.50%
3 months-4.91%
6 months-18.86%
Current year-25.96%
1 week 2.67
Extreme 2.67
2.76
1 month 2.57
Extreme 2.57
3.06
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.15
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 19/12/2013
Director of Finance/CFO 51 21/02/2012
Director of Finance/CFO 36 15/08/2022
Director TitleAgeSince
Director/Board Member 74 30/11/2008
Chairman 71 19/12/2013
Director/Board Member 63 31/05/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Financial Officer

2,967 0.0096%
18/03/26 Free

Chief Executive Officer

475,424 1.5318%
18/03/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%+1.12%-24.72%-53.44% 90.38M
-2.10%-1.64%+45.10%-2.45% 80.91B
-0.78%-1.52%-18.45%-36.25% 60.46B
-3.59%-9.04%+465.16%+30.37% 56.02B
-1.77%-5.26%-9.16%+29.36% 49.63B
-1.50%-7.57%-2.53%+147.27% 45.88B
-3.77%-1.64%+50.34%-17.95% 31.4B
-1.85%-0.49%+43.72%+94.44% 25.22B
-2.00%-3.54%-2.68%+156.40% 22.25B
-1.51%-1.01%+62.83%+103.07% 16.59B
Average -1.93%-1.28%+60.96%+45.08% 38.84B
Weighted average by Cap. -2.09%-1.44%+81.58%+37.40%

Financials

2026 *2027 *
Net sales 78.79M 67.75M 63.74M 58.16M 109M 7.47B 109M 755M 292M 3.82B 296M 289M 12.15B 113M 97.37M 91.61M 83.6M 156M 10.74B 157M 1.09B 420M 5.49B 425M 416M 17.46B
Net income 88.25M 75.87M 71.38M 65.14M 122M 8.37B 122M 846M 327M 4.28B 331M 324M 13.61B -37.81M -32.51M -30.59M -27.91M -52.09M -3.58B -52.36M -362M -140M -1.83B -142M -139M -5.83B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
08/09/26 US$2.710 -0.37% 263,047
04/09/26 US$2.720 +0.37% 168,144
03/09/26 US$2.710 -0.73% 148,109
02/09/26 US$2.730 +1.87% 279,774
01/09/26 US$2.680 -2.01% 605,780
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.710USD
Average target price
11.00USD
Spread / Average Target
+305.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!